Literature DB >> 23714403

Evaluation of class switch recombination in B lymphocytes of patients with common variable immunodeficiency.

Amir Salek Farrokhi1, Asghar Aghamohammadi, Shabnam Pourhamdi, Payam Mohammadinejad, Hassan Abolhassani, Seyed Mohammad Moazzeni.   

Abstract

Common variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized by hypogammaglobulinemia and recurrent bacterial infections. Impaired antibody production in these patients is due to defect in B-cell differentiation into specific plasma cells. Class switch recombination (CSR), which plays a critical role in the production of different immunoglobulin isotypes, may be defective in a group of CVID patients. The aim of this study was to investigate the CSR process in B cells of CVID patients, by evaluating the expression of IgE mRNA and production of its protein in an IgE inductive medium. Peripheral blood mononuclear cells (PBMCs) from 29 CVID patients and 21 healthy controls were isolated and cultured in the presence of rhIL-4 and CD40L. IgE mRNA and IgE protein were measured by RT-PCR and ELISA techniques, respectively. Normal production of IgE mRNA was recorded in 23 out of 29 patients (79.31%) as well as all controls; while the remaining 6 patients (20.69%) were unable to express IgE mRNA indicating a defect in CSR. PBMCs of 16 out of 29 patients (55.2%) could not produce normal amounts of IgE compared with controls, after being stimulated by IL-4 and CD40L. Post B cell stimulation IgE production was impaired in about half of studied CVID patients. Defects in processes occur following the CSR process such as IgE mRNA transcription, protein production, and secretion can be the causative mechanism of CVID in patients with normal mRNA expression of the immunoglobulin but impaired protein production. Determination of these defects can help to clarify the various underlying mechanisms responsible for the development of CVID.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Class switch recombination; Common variable immunodeficiency; Immune dysregulation

Mesh:

Substances:

Year:  2013        PMID: 23714403     DOI: 10.1016/j.jim.2013.05.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

2.  Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.

Authors:  Hassan Abolhassani; Yasser M El-Sherbiny; Gururaj Arumugakani; Clive Carter; Stephen Richards; Dylan Lawless; Philip Wood; Matthew Buckland; Marzieh Heydarzadeh; Asghar Aghamohammadi; Sophie Hambleton; Lennart Hammarström; Siobhan O Burns; Rainer Doffinger; Sinisa Savic
Journal:  J Clin Immunol       Date:  2019-12-20       Impact factor: 8.317

3.  Expression of activation-induced cytidine deaminase gene in B lymphocytes of patients with common variable immunodeficiency.

Authors:  Hassan Abolhassani; Amir Salek Farrokhi; Shabnam Pourhamdi; Payam Mohammadinejad; Bamdad Sadeghi; Seyed-Mohammad Moazzeni; Asghar Aghamohammadi
Journal:  Iran J Pediatr       Date:  2013-08       Impact factor: 0.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.